IDIBELL - Bellvitge Biomedical Research Institute

What IDIBELL - Bellvitge Biomedical Research Institute does

IDIBELL (Institut d'Investigació Biomèdica de Bellvitge) is a private non-profit biomedical research foundation registered in Catalonia since 1989 and headquartered in L'Hospitalet de Llobregat within the Bellvitge Health Campus. The institute operates as a multi-institutional consortium governed by a Board of Trustees comprising the Generalitat de Catalunya, University of Barcelona, Bellvitge University Hospital, Catalan Institute of Oncology, Hospital de Viladecans, and the City of L'Hospitalet de Llobregat. IDIBELL organizes over 1,000 researchers across 72 research groups, 9 research programs, and 4 major thematic areas: cancer, neurosciences, translational medicine, and regenerative medicine, with the 2026 launch of REMMA Bellvitge adding the first adult rare disease program in Spain.

The institute's technology base spans whole genome sequencing bioinformatics (notably the adapted GRIDSS pipeline applied across ~10,000 individuals for cancer predisposition analysis), AI-based computer vision (the SEPI-IA prototype for interstitial lung disease CT analysis), and biomarker development (the MAP-AD® Alzheimer's progression blood test, CE marked for EU clinical use in 2025). The HUB-ICO-IDIBELL Biobank provides shared biological sample infrastructure, while the Solve-RD consortium participation extends rare disease genomics reach.

IDIBELL does not commercialize products directly; the revenue model is grant-driven (ISCIII, European Commission, ERC, Generalitat de Catalunya, Next Generation EU via CDTI) supplemented by donations, technology transfer (spin-offs and licensing), and translational services delivered through the EATRIS Expert Centre network. Go-to-market is community-led via research collaborations with hospitals, academic institutions, and industry partners such as ADmit Therapeutics, GMV, and Tecnalia. The institute holds ISCIII accreditation (2009), HR Excellence in Research (2015), EATRIS Expert Centre status (2023), OECI membership (2025), and the maximum European accreditation for comprehensive cancer care at Campus Salut Bellvitge (2025).

Name

IDIBELL - Bellvitge Biomedical Research Institute

Legal name

INSTITUT D'INVESTIGACIÓ BIOMÈDICA DE BELLVITGE

Website

https://idibell.cat

Company type

Private

Founded year

1989

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

IDIBELL is a Catalan non-profit biomedical research foundation running 1,000+ researchers across cancer, neurosciences, translational and regenerative medicine, integrated with Bellvitge Hospital, ICO, and the University of Barcelona. It funds research via ISCIII and EU grants and develops diagnostic tools such as the CE-marked MAP-AD Alzheimer's blood test.

Ownership category

akta.pro rank

Product category

Biomedical Research Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (54171)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Biomedical Sciences & Medical Research Institutes (University-Based) (EDAHAGAI)

akta.pro secondary industry

Translational Medicine & Biomarkers (HLAIALAF)

Keywords

• Biomedical research
• Translational medicine
• Cancer research
• Clinical research
• Regenerative medicine

Headquarters

HQ city

Hospitalet De Llobregat

HQ country

Spain

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure

Revenue model

1. Government Research Grants and Funding: IDIBELL receives funding from national and European government sources including ISCIII, European Commission, European Research Council, FECyT, and regional Catalan government
2. Donations and Fundraising: Individual and corporate donations, crowdfunding campaigns, inheritance programs, and Bizum payments for research support
3. Public Procurement - CDTI: Pre-commercial public procurement funding through CDTI for technology development, such as the 5 million euro SEPI-IA project funded by Next Generation EU under PERTE for Advanced Health
4. Innovation and Technology Transfer: Spin-off companies, licensing agreements, and enterprise services for industry collaboration in translational research

Go-to-market motion1 record

Distribution channels4 records

Marketing channels6 records

Core offering

IDIBELL is a biomedical research institute conducting integrated basic and clinical research across four major areas: cancer, neurosciences, translational medicine, and regenerative medicine. The institute operates 72 research groups and 9 research programs, translating laboratory discoveries into clinical applications through partnerships with hospitals, industry, and academic institutions. It also engages in technology transfer, spin-off creation, and licensing of research outputs including diagnostic tools and AI prototypes.

Product overview

IDIBELL is a biomedical research institute (not a product company) that conducts research in cancer, neurosciences, translational medicine, and regenerative medicine. The institute offers research services and collaborates on diagnostic tools including a whole genome sequencing service for hereditary cancer (Solve-RD project), the SEPI-IA AI prototype for interstitial lung disease prediction, and the MAP-AD® blood test for Alzheimer's progression. These offerings are research and clinical collaboration services rather than commercial software products.

Differentiator

Problem solved

Functional benefit

Brands

• BioCluster: A partnership initiative between multiple Catalan institutions aiming to establish the Barcelona metropolitan area as a biomedical hub, projecting 30,000 direct jobs and an economic impact of 4,400 million euros.
• REMMA Bellvitge

Products and services

• Hereditary Cancer Genetic Diagnostics (Solve-RD Project)
• SEPI-IA
• MAP-AD

Quantifiable outcome

• 6% increase in diagnostic yield for hereditary cancer syndromes through whole genome sequencing reanalysis in 98 young patients
• +3 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature4 records

Partnerships

13 partnerships are on record, tiered core and minor.

• Catalan Institute of Oncology (ICO)coreStrategic or Co-development Partner · 13 May 2026Joint research with IDIBELL on hereditary cancer diagnostics, including whole genome sequencing reanalysis and GRIDSS bioinformatics tool adaptation for cancer predisposition gene analysis.
• Solve-RD ConsortiumcoreStrategic or Co-development Partner · 13 May 2026European research consortium for solving rare diseases where IDIBELL researchers reanalyzed whole genome sequencing data from young patients with suspected hereditary cancer syndromes.
• GMV and TecnaliacoreTechnology or Integration · 25 March 2026Technology firms that developed the SEPI-IA AI prototype for Hospital Universitario de Bellvitge through CDTI's Pre-Commercial Public Procurement mechanism. Four-year development funded with 5 million euros from Next Generation EU funds.
• CDTI InnovacióncoreStrategic or Co-development Partner · 25 March 2026Spanish innovation agency that formally delivered the SEPI-IA prototype and managed the 5 million euro funding from Next Generation EU under PERTE for Advanced Health.
• ADmit TherapeuticscoreStrategic or Co-development Partner · 19 September 2025Developer of MAP-AD® blood test for predicting Alzheimer's progression, with validation support from IDIBELL and Bellvitge University Hospital. Test received CE marking for clinical use across EU.
• BioCluster Initiative PartnerscoreStrategic or Co-development Partner · 7 November 2024Partnership between multiple Catalan institutions aiming to establish Barcelona metropolitan area as biomedical hub, projecting 30,000 direct jobs and 4,400 million euros economic impact.
• EATRIScoreStrategic or Co-development Partner · 1 April 2023European Research Infrastructure for Translational Medicine. IDIBELL is Expert Centre offering regulatory support, innovation management, and translational viability services through this network.
• P-CMR[C] - Program of Clinical Translation of Regenerative Medicine of CataloniacoreStrategic or Co-development Partner · 1 January 2017Clinical translation program of regenerative medicine in Catalonia, with Barcelona Center for Regenerative Medicine (CMR[B]) now part of IDIBELL.
• University of BarcelonacoreStrategic or Co-development PartnerIntegration of University of Barcelona Bellvitge Campus research with IDIBELL, part of HUBc Campus of International Excellence.
• Bellvitge University HospitalcoreStrategic or Co-development PartnerMain clinical partner integrating research with healthcare delivery, part of Catalan Institute of Health.
• Hospital de ViladecanscoreStrategic or Co-development PartnerPart of Catalan Institute of Health, integrated with IDIBELL research activities.
• City of L'Hospitalet de LlobregatminorStrategic or Co-development PartnerMunicipal government partner supporting biomedical ecosystem development through BioCluster initiative.
• HUB-ICO-IDIBELL BiobankcoreStrategic or Co-development PartnerJoint biobank with Bellvitge University Hospital and Catalan Institute of Oncology for biological sample collection and research.

Scale indicators11 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• CRG - Centre for Genomic Regulation: Barcelona-based biomedical research institute with strengths in genomics, systems biology, and disease mechanisms. Comparable CERCA centre governance, similar headcount band, and shared EU and Catalan funding pipelines.
• IDIBAPS - Institut d'Investigacions Biomèdiques August Pi i Sunyer: Barcelona-based biomedical research institute affiliated with the University of Barcelona, integrating basic and clinical research in cancer, neurosciences, and translational medicine. Most direct comparable peer in terms of structure, funding mix, and translational mission.
• IRB Barcelona - Institute for Research in Biomedicine: Catalan biomedical research institute focused on cancer, cell biology, and computational biology, with similar grant-funding model and translational pipeline. Operates in the same regional ecosystem and competes for overlapping EATRIS and EU funding.
• CNIO - Spanish National Cancer Research Centre: Spain's flagship public cancer research centre covering cancer biology, therapeutics, and translational research. Closest peer for IDIBELL's cancer programmes, sharing ISCIII oversight and CERCA-style public funding.
• VHIO - Vall d'Hebron Institute of Oncology: Catalan oncology research institute embedded in Vall d'Hebron University Hospital, focused on translational and clinical oncology. Competes with IDIBELL/ICO cancer programmes for EU grants and industry-sponsored trials.
• IGTP - Germans Trias i Pujol Research Institute: Catalan biomedical research institute accredited by ISCIII and integrated with a public university hospital. Comparable scale, translational focus, and Catalan/EU funding model.

Broad incumbents

• Karolinska Institutet: Much larger Swedish biomedical university with parallel cancer, neuroscience, and translational research programmes and significant EATRIS overlap. Useful benchmark for long-run scale and funding diversification.
• Francis Crick Institute: Large UK biomedical research institute with cancer, neuroscience, and translational programmes funded through mixed public, charity, and industry sources. Comparable translational platform but at substantially larger scale.
• Wellcome Sanger Institute: UK-based genomics and biomedical research institute with strong hereditary disease and cancer programmes, including the Solve-RD partner. Comparable in leveraging genomic data for diagnostic yield improvements.
• Institut Pasteur: Major European life sciences research institute spanning infectious disease, cancer, and neuroscience with similar public-grant and licensing revenues. Relevant benchmark for international translational reach.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/idibell_cat
• YouTubeyoutube.com/user/canalidibell
• Facebookfacebook.com/Idibell
• LinkedInlinkedin.com/company/idibell
• Instagraminstagram.com/idibell_cat

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about IDIBELL - Bellvitge Biomedical Research Institute